Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 7Melanoma 4Colitis 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Lung Neoplasms 2Inflammatory Bowel Diseases 2Inflammation 2Fatigue 2Depressive Disorder, Major 2Depression 2Colitis, Ulcerative 2Vasculitis 1Takayasu Arteritis 1Syndrome 1Stroke 1Stevens-Johnson Syndrome 1Spondylitis, Ankylosing 1Skin Neoplasms 1Psoriasis 1Precancerous Conditions 1Pemphigoid, Benign Mucous Membrane 1Infections 1Hypertension 1Hepatitis C 1Hematologic Neoplasms 1Graft vs Host Disease 1Drug-Related Side Effects and Adverse Reactions 1Depressive Disorder, Treatment-Resistant 1Cytokine Release Syndrome 1

Interventions

Saline Solution 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Depressive Disorder, Treatment-Resistant × Infliximab × Clear all
NCT00463580 2025-07-08

Infliximab

Emory University

Phase 4 Completed
60 enrolled 15 charts

Bipolar Disorder, Depression, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡